Warning: Undefined variable $page_cluster_id in /home3/thegood9/public_html/website_70aad9ea/header.php on line 29



Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Tag Directory / HEALTHCARE     showing 1–3 of 3   RSS


for: Thursday, March 05, 2026



Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy

livescience - An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.

AI Summary: An experimental treatment markedly cut seizures and eased symptoms in children with Dravet syndrome, offering families dramatic improvements where few options existed. Early clinical data show promising safety and efficacy signals, but researchers caution larger, longer trials and regulatory review are needed before this becomes a routine option.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #infanthealth

2 months / livescience

2 months / bbc

2 months / medicalxpress

2 months / medicalxpress


Back to Top / Thursday, March 5, 2026, 4:23 pm / permalink 20233 / 4 stories in 2 months /

Amazon launches Amazon Connect Health

Naomi Diaz / beckershospitalreview - Amazon Web Services has launched Amazon Connect Health, an artificial intelligence tool designed to automate administrative tasks for health systems and improve patient access to care. Here are six things to know about Amazon Connect Health: Amazon Connec…

AI Summary: Amazon Web Services rolled out a suite of agentic AI tools under the Amazon Connect Health name to take on the administrative drudgery of healthcare — scheduling, ambient note‑taking, coding and patient engagement. The platform promises to automate front‑office tasks, generate clinical summaries, and integrate with provider workflows, aiming to free clinicians from endless paperwork.

#healthcare #digitalhealth #hospitaloperations #healthcarefinance

2 months / medicalxpress

2 months / fiercehealthcare

2 months / medicalxpress

2 months / medicalxpress

2 months / livescience

2 months / oncodaily

2 months / bbc

2 months / fiercehealthcare

2 months / fiercehealthcare

2 months / medicalxpress

2 months / fiercehealthcare


Back to Top / Thursday, March 5, 2026, 11:23 am / permalink 20205 / 33 stories in 2 months /

Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less

esmo - Findings from the POSEIDON meta-analysis of the MARCAP consortium

AI Summary: A pooled POSEIDON meta-analysis from the MARCAP consortium found that adding androgen-deprivation therapy to post‑operative radiotherapy for recurrent prostate cancer with PSA ≤0.5 ng/mL does not improve outcomes meaningfully. In short: the extra hormonal punch may not be worth the side effects many patients will endure.

#healthcare #pharmaceuticals #publichealth #oncology

2 months / esmo

2 months / oncodaily

3 months / sootoday


Back to Top / Thursday, March 5, 2026, 3:23 am / permalink 20175 / 3 stories in 2 months /

Back to Top


HEALTHCARE Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Eli Lilly, Drug Pricing, Neuroscience, Research Funding and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.